{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"ss-31-plantar-fasciitis","title":"SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review","body":"## What's breaking down if you have Plantar Fasciitis\n\nPlantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased cell death in tenocyte-like cells, and reduced ability to handle mechanical stress from walking or standing.\n\nIf your fascia cells have mitochondrial dysfunction, energy production drops and repair slows. This creates a gap where breakdown outruns regeneration. Mitochondrial membrane potential falls, reactive oxygen species handling weakens, and genes linked to matrix breakdown rise. These layers matter because plantar fascia is under constant load; poor cellular energy makes recovery harder.\n\nNo direct human data links plantar fasciitis to SS-31. The closest evidence comes from degenerative tendon cells, which share features with fascia degeneration.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. You are reading about Plantar Fasciitis — what breaks down matters before any compound name.\n2. Therefore for you: If mitochondrial dysfunction in fascia cells is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\nSS-31 concentrates in the inner mitochondrial membrane and stabilizes cardiolipin. In degenerative tenocytes from human tendon biopsies, treatment reduced the fraction of cells with depolarized mitochondria and improved mitochondrial number and size seen on electron microscopy. Superoxide dismutase activity rose after treatment. Matrix metalloproteinase-1 expression fell, and fatty acid-binding protein 4 expression dropped. Cell viability showed small improvement.\n\nIf your plantar fascia cells behave like those degenerative tenocytes, SS-31 could support mitochondrial structure and function. That might allow better ATP production for collagen maintenance and reduce signals that promote further breakdown. The study used cultured cells from patients with rotator cuff issues, not foot fascia, so direct translation remains untested.\n\nSS-31 does not act as a pain suppressor or anti-inflammatory drug in the classic sense. It addresses cellular energy deficits that may underlie poor tissue repair in degenerative conditions.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer. If your condition profile includes other degeneration layers such as mechanical overload or inflammation, those would require separate approaches. SS-31 addresses energy production inside cells so repair pathways have a better chance to keep pace with daily loading on the fascia.\n\n## What the evidence actually shows\n\nThe key study is an in vitro model using tenocytes from human degenerative supraspinatus tendons versus healthy hamstring tendons (Zhang et al., 2022, Am J Sports Med). Researchers cultured cells at passage 1 and exposed degenerative cells to 1 μM SS-31 for 72 hours. They measured mitochondrial depolarization, morphology via transmission electron microscopy, antioxidant enzyme activity, gene expression, and cell viability.\n\nFindings: degenerative tenocytes had more depolarized mitochondria and smaller, fewer mitochondria. SS-31 reversed these changes. Antioxidant activity improved. Remodeling and fatty infiltration genes normalized. The study is preclinical (human cells in culture) and does not prove effects in living people with plantar fasciitis.\n\nHuman trials of SS-31 exist for primary mitochondrial myopathy and Barth syndrome. One phase 2/3 trial in Barth syndrome showed functional improvements in the open-label extension but missed primary endpoints in the blinded phase. No trials test SS-31 in plantar fasciitis or any foot condition.\n\n## What scientists say\n\nThe tendinopathy paper concludes that mitochondrial dysfunction appears in degenerative tenocytes and SS-31 may improve mitochondrial function to promote healing. Authors note clinical relevance for tendinopathy but call for further work. Broader reviews describe SS-31 as a cardiolipin stabilizer that supports electron transport and reduces oxidative stress in multiple mitochondrial disease models. No published statements address plantar fasciitis specifically.\n\n## What people say on Reddit\n\nNo posts or threads were identified discussing SS-31 or elamipretide in the context of plantar fasciitis or foot pain. Searches returned zero relevant anecdotes.\n\n## What people say on X\n\nNo posts were identified linking SS-31 to plantar fasciitis. General discussions of the peptide focus on Barth syndrome approval or mitochondrial myopathy trials.\n\n## What we do not know\n\nNo human trials exist for SS-31 in plantar fasciitis. No animal models of plantar fasciitis treated with SS-31 have been published. Whether improved mitochondrial function in cultured tendon cells translates to fascia repair in vivo remains unknown. Long-term safety and functional outcomes in musculoskeletal tissues are unstudied for this indication. Weight loss can reduce compressive forces on the plantar fascia (roughly 4 lb per pound lost), but SS-31 itself has no documented effect on body weight.\n\n## Safety and limits\n\nSS-31 has been tested in human trials for mitochondrial myopathy and Barth syndrome with generally good tolerability reported. Common side effects in those studies were mild and included injection-site reactions. The compound received FDA approval for Barth syndrome in 2025. All other uses remain investigational. No data exist on interactions with common plantar fasciitis treatments or on long-term use in otherwise healthy individuals. This review reports published findings only and does not constitute guidance.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-plantar-fasciitis/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Degenerative tenocytes from human tendon show increased mitochondrial depolarization that decreases after SS-31 treatment in cell culture.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only direct cellular data on SS-31 in degenerative tendon cells relevant to fascia.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SS-31 improved mitochondrial morphology, superoxide dismutase activity, and reduced MMP-1 and FABP4 gene expression in degenerative tenocytes.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Details the specific mitochondrial and gene changes observed.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human clinical trials of SS-31 have been conducted in plantar fasciitis.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Establishes the evidence gap for the target condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"SS-31 received FDA approval for Barth syndrome in 2025 based on extension-phase functional improvements.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents the approved indication and trial outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No Reddit or X anecdotes mention SS-31 for plantar fasciitis.","section":"What people say on Reddit","tier":"anecdotal","source_ids":[],"source_status":"unsourced","why_material":"Confirms absence of community reports.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35862638/","title":"Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model","quote":"There are changes in mitochondrial structure and function in tenocytes derived from degenerative tendons, and SS-31, as a mitochondrial protectant, could improve mitochondrial function and promote the healing of tendinopathy.","summary":"In vitro study on human tenocytes showing SS-31 effects on mitochondria and gene expression in degenerative cells.","claim_ids":["c1","c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:48:52.430Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"f097611dea886decfb90f89c1a79b20268a7ad37e3160858b599c2aff95e8df3"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35862638/","title":"Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model","quote":"The potential of SS-31 in treating tendinopathy has not been explored.","summary":"Explicit statement of no prior exploration in tendinopathy, extending to plantar fasciitis.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:48:52.430Z","link_status":"ok","quote_status":"verified","prev":"f097611dea886decfb90f89c1a79b20268a7ad37e3160858b599c2aff95e8df3","hash":"27a377688ad1ac77288b9da8d28bbd8a955aa8490671966402bface18b98cda9"},{"id":"s3","type":"news","url":"https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/","title":"FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31","quote":"The recent FDA approval of elamipretide is for the treatment of a rare disease","summary":"Reports 2025 FDA approval for Barth syndrome and trial context.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:48:52.430Z","link_status":"ok","quote_status":"unverified","prev":"27a377688ad1ac77288b9da8d28bbd8a955aa8490671966402bface18b98cda9","hash":"1e32ffca2ef4addbee999fa0885d54ddc81e0f73ab715f6ffef03da5a9527cad"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:48:53.088Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Plantar Fasciitis\n\nPlantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased cell death in tenocyte-like cells, and reduced ability to handle mechanical stress from walking or standing.\n\nIf your fascia cells have mitochondrial dysfunction, energy production drops and repair slows. This creates a gap where breakdown outruns regeneration. Mitochondrial membrane potential falls, reactive oxygen species handling weakens, and genes linked to matrix breakdown rise. These layers matter because plantar fascia is under constant load; poor cellular energy makes recovery harder.\n\nNo direct human data links plantar fasciitis to SS-31. The closest evidence comes from degenerative tendon cells, which share features with fascia degeneration.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. You are reading about Plantar Fasciitis — what breaks down matters before any compound name.\n2. Therefore for you: If mitochondrial dysfunction in fascia cells is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\nSS-31 concentrates in the inner mitochondrial membrane and stabilizes cardiolipin. In degenerative tenocytes from human tendon biopsies, treatment reduced the fraction of cells with depolarized mitochondria and improved mitochondrial number and size seen on electron microscopy. Superoxide dismutase activity rose after treatment. Matrix metalloproteinase-1 expression fell, and fatty acid-binding protein 4 expression dropped. Cell viability showed small improvement.\n\nIf your plantar fascia cells behave like those degenerative tenocytes, SS-31 could support mitochondrial structure and function. That might allow better ATP production for collagen maintenance and reduce signals that promote further breakdown. The study used cultured cells from patients with rotator cuff issues, not foot fascia, so direct translation remains untested.\n\nSS-31 does not act as a pain suppressor or anti-inflammatory drug in the classic sense. It addresses cellular energy deficits that may underlie poor tissue repair in degenerative conditions.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer. If your condition profile includes other degeneration layers such as mechanical overload or inflammation, those would require separate approaches. SS-31 addresses energy production inside cells so repair pathways have a better chance to keep pace with daily loading on the fascia.\n\n## What the evidence actually shows\n\nThe key study is an in vitro model using tenocytes from human degenerative supraspinatus tendons versus healthy hamstring tendons (Zhang et al., 2022, Am J Sports Med). Researchers cultured cells at passage 1 and exposed degenerative cells to 1 μM SS-31 for 72 hours. They measured mitochondrial depolarization, morphology via transmission electron microscopy, antioxidant enzyme activity, gene expression, and cell viability.\n\nFindings: degenerative tenocytes had more depolarized mitochondria and smaller, fewer mitochondria. SS-31 reversed these changes. Antioxidant activity improved. Remodeling and fatty infiltration genes normalized. The study is preclinical (human cells in culture) and does not prove effects in living people with plantar fasciitis.\n\nHuman trials of SS-31 exist for primary mitochondrial myopathy and Barth syndrome. One phase 2/3 trial in Barth syndrome showed functional improvements in the open-label extension but missed primary endpoints in the blinded phase. No trials test SS-31 in plantar fasciitis or any foot condition.\n\n## What scientists say\n\nThe tendinopathy paper concludes that mitochondrial dysfunction appears in degenerative tenocytes and SS-31 may improve mitochondrial function to promote healing. Authors note clinical relevance for tendinopathy but call for further work. Broader reviews describe SS-31 as a cardiolipin stabilizer that supports electron transport and reduces oxidative stress in multiple mitochondrial disease models. No published statements address plantar fasciitis specifically.\n\n## What people say on Reddit\n\nNo posts or threads were identified discussing SS-31 or elamipretide in the context of plantar fasciitis or foot pain. Searches returned zero relevant anecdotes.\n\n## What people say on X\n\nNo posts were identified linking SS-31 to plantar fasciitis. General discussions of the peptide focus on Barth syndrome approval or mitochondrial myopathy trials.\n\n## What we do not know\n\nNo human trials exist for SS-31 in plantar fasciitis. No animal models of plantar fasciitis treated with SS-31 have been published. Whether improved mitochondrial function in cultured tendon cells translates to fascia repair in vivo remains unknown. Long-term safety and functional outcomes in musculoskeletal tissues are unstudied for this indication. Weight loss can reduce compressive forces on the plantar fascia (roughly 4 lb per pound lost), but SS-31 itself has no documented effect on body weight.\n\n## Safety and limits\n\nSS-31 has been tested in human trials for mitochondrial myopathy and Barth syndrome with generally good tolerability reported. Common side effects in those studies were mild and included injection-site reactions. The compound received FDA approval for Barth syndrome in 2025. All other uses remain investigational. No data exist on interactions with common plantar fasciitis treatments or on long-term use in otherwise healthy individuals. This review reports published findings only and does not constitute guidance.","claims":[{"id":"c1","text":"Degenerative tenocytes from human tendon show increased mitochondrial depolarization that decreases after SS-31 treatment in cell culture.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only direct cellular data on SS-31 in degenerative tendon cells relevant to fascia.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SS-31 improved mitochondrial morphology, superoxide dismutase activity, and reduced MMP-1 and FABP4 gene expression in degenerative tenocytes.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Details the specific mitochondrial and gene changes observed.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human clinical trials of SS-31 have been conducted in plantar fasciitis.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Establishes the evidence gap for the target condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"SS-31 received FDA approval for Barth syndrome in 2025 based on extension-phase functional improvements.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents the approved indication and trial outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No Reddit or X anecdotes mention SS-31 for plantar fasciitis.","section":"What people say on Reddit","tier":"anecdotal","source_ids":[],"source_status":"unsourced","why_material":"Confirms absence of community reports.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35862638/","title":"Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model","quote":"There are changes in mitochondrial structure and function in tenocytes derived from degenerative tendons, and SS-31, as a mitochondrial protectant, could improve mitochondrial function and promote the healing of tendinopathy.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35862638/","title":"Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model","quote":"The potential of SS-31 in treating tendinopathy has not been explored.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"news","url":"https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/","title":"FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31","quote":"The recent FDA approval of elamipretide is for the treatment of a rare disease","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":15473,"tokens_out":2862,"cost":0.02649625,"prev_hash":"genesis","hash":"f3d7ac422dfb8fbf989b85107e7d16458941364a50c95d8156e970faf4432d2c"}],"provenance":[{"ts":"2026-06-29T23:48:53.088Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Plantar Fasciitis\nSlug: ss-31-plantar-fasciitis\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Plantar fasciitis\",\"condition_key\":\"plantar-fasciitis\",\"primary_peptide\":\"ss-31\",\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":true,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Plantar fasciitis\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"You are reading about **Plantar fasciitis** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Plantar fasciitis** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down if you have Pla","response":"{\n  \"slug\": \"ss-31-plantar-fasciitis\",\n  \"title\": \"SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review\",\n  \"body\": \"## What's breaking down if you have Plantar Fasciitis\\n\\nPlantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased cell death in tenocyte-like cells, and reduced ability to handle mechanical stress from walking or standing.\\n\\nIf your fascia cells have mitochondrial dysfunction, energy production drops and repair slows. This creates a gap where breakdown outruns regeneration. Mitochondrial membrane potential falls, reactive oxygen species handling weakens, and genes linked to matrix breakdown rise. These layers matter because plantar fascia is under constant load; poor cellular energy makes recovery harder.\\n\\nNo direct human data links plantar fasciitis to SS-31. The closest evidence comes from degenerative tendon cells, which share features with fascia degeneration.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\n1. You are reading about Plantar Fasciitis — what breaks down matters before any compound name.\\n2. Therefore for you: If mitochondrial dysfunction in fascia cells is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nSS-31 concentrates in the inner mitochondrial membrane and stabilizes cardiolipin. In degenerative tenocytes from human tendon biopsies, treatment reduced the fraction of cells with depolarized mitochondria and improved mitochondrial number and size seen on electron microscopy. Superoxide dismutase activity rose after treatment. Matrix metalloproteinase-1 expression fell, and fatty acid-binding protein 4 expression dropped. Cell viability showed small improvement.\\n\\nIf your plantar fascia cells behave like those degenerative tenocytes, SS-31 could support mitochondrial structure and function. That might a","tokens_in":15473,"tokens_out":2862,"cost":0,"prev":"genesis","hash":"c78f0d4e578d6a6f28b942eb8d06b734631f6232dff58ce6649b0ca364672c66"},{"ts":"2026-07-17T02:42:07.015Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-plantar-fasciitis","response":"25 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c78f0d4e578d6a6f28b942eb8d06b734631f6232dff58ce6649b0ca364672c66","hash":"0411ce842fed4a5498cb6005be15f12495be19dea3b1399d63b6b46865f63c41"}],"energy":{"passes":2,"tokens_in":15473,"tokens_out":2862,"tokens_total":18335,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"0411ce842fed4a5498cb6005be15f12495be19dea3b1399d63b6b46865f63c41"},"posted_at":"2026-06-29T21:33:24.268Z","created_at":"2026-06-29T21:33:24.268Z","updated_at":"2026-07-17T02:42:07.015Z","machine":{"shape":"article.machine/v1","slug":"ss-31-plantar-fasciitis","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-plantar-fasciitis","json":"https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis","bundle":"https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-plantar-fasciitis","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-plantar-fasciitis\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-plantar-fasciitis\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-plantar-fasciitis\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-plantar-fasciitis","json":"/api/articles/ss-31-plantar-fasciitis","markdown":"/api/articles/ss-31-plantar-fasciitis/bundle?format=markdown","skill":"/api/articles/ss-31-plantar-fasciitis/skill","topology":"/api/articles/ss-31-plantar-fasciitis/topology","versions":"/api/articles/ss-31-plantar-fasciitis/revisions","invocations":"/api/articles/ss-31-plantar-fasciitis/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-plantar-fasciitis","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"7f3f2de0ce8a5034201c1ca4a7cd7a9fffd69583f2df687e57ca7841866b16ae","object":{"object_type":"article-object","identity":{"id":"article:ss-31-plantar-fasciitis","slug":"ss-31-plantar-fasciitis","title":"SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/ss-31-plantar-fasciitis","role":"explain","audience":"human"},"skill":{"route":"/api/articles/ss-31-plantar-fasciitis/skill","role":"direct behavior","audience":"model","content":"---\nname: ss-31-plantar-fasciitis\ndescription: Apply the SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/ss-31-plantar-fasciitis). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/ss-31-plantar-fasciitis.\n- Read claims and relationships at /api/articles/ss-31-plantar-fasciitis/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have Plantar Fasciitis Plantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased \n\n## Representations\n\n- Human: /a/ss-31-plantar-fasciitis\n- JSON: /api/articles/ss-31-plantar-fasciitis\n- Relationships: /api/articles/ss-31-plantar-fasciitis/topology\n- History: /api/articles/ss-31-plantar-fasciitis/revisions\n"},"json":{"route":"/api/articles/ss-31-plantar-fasciitis","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/ss-31-plantar-fasciitis/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","ss","31","plantar","fasciitis"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/ss-31-plantar-fasciitis/invocations?status=success","failure_events":"/api/articles/ss-31-plantar-fasciitis/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"ss-31-plantar-fasciitis","title":"SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review","body":"## What's breaking down if you have Plantar Fasciitis\n\nPlantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased cell death in tenocyte-like cells, and reduced ability to handle mechanical stress from walking or standing.\n\nIf your fascia cells have mitochondrial dysfunction, energy production drops and repair slows. This creates a gap where breakdown outruns regeneration. Mitochondrial membrane potential falls, reactive oxygen species handling weakens, and genes linked to matrix breakdown rise. These layers matter because plantar fascia is under constant load; poor cellular energy makes recovery harder.\n\nNo direct human data links plantar fasciitis to SS-31. The closest evidence comes from degenerative tendon cells, which share features with fascia degeneration.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. You are reading about Plantar Fasciitis — what breaks down matters before any compound name.\n2. Therefore for you: If mitochondrial dysfunction in fascia cells is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\nSS-31 concentrates in the inner mitochondrial membrane and stabilizes cardiolipin. In degenerative tenocytes from human tendon biopsies, treatment reduced the fraction of cells with depolarized mitochondria and improved mitochondrial number and size seen on electron microscopy. Superoxide dismutase activity rose after treatment. Matrix metalloproteinase-1 expression fell, and fatty acid-binding protein 4 expression dropped. Cell viability showed small improvement.\n\nIf your plantar fascia cells behave like those degenerative tenocytes, SS-31 could support mitochondrial structure and function. That might allow better ATP production for collagen maintenance and reduce signals that promote further breakdown. The study used cultured cells from patients with rotator cuff issues, not foot fascia, so direct translation remains untested.\n\nSS-31 does not act as a pain suppressor or anti-inflammatory drug in the classic sense. It addresses cellular energy deficits that may underlie poor tissue repair in degenerative conditions.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer. If your condition profile includes other degeneration layers such as mechanical overload or inflammation, those would require separate approaches. SS-31 addresses energy production inside cells so repair pathways have a better chance to keep pace with daily loading on the fascia.\n\n## What the evidence actually shows\n\nThe key study is an in vitro model using tenocytes from human degenerative supraspinatus tendons versus healthy hamstring tendons (Zhang et al., 2022, Am J Sports Med). Researchers cultured cells at passage 1 and exposed degenerative cells to 1 μM SS-31 for 72 hours. They measured mitochondrial depolarization, morphology via transmission electron microscopy, antioxidant enzyme activity, gene expression, and cell viability.\n\nFindings: degenerative tenocytes had more depolarized mitochondria and smaller, fewer mitochondria. SS-31 reversed these changes. Antioxidant activity improved. Remodeling and fatty infiltration genes normalized. The study is preclinical (human cells in culture) and does not prove effects in living people with plantar fasciitis.\n\nHuman trials of SS-31 exist for primary mitochondrial myopathy and Barth syndrome. One phase 2/3 trial in Barth syndrome showed functional improvements in the open-label extension but missed primary endpoints in the blinded phase. No trials test SS-31 in plantar fasciitis or any foot condition.\n\n## What scientists say\n\nThe tendinopathy paper concludes that mitochondrial dysfunction appears in degenerative tenocytes and SS-31 may improve mitochondrial function to promote healing. Authors note clinical relevance for tendinopathy but call for further work. Broader reviews describe SS-31 as a cardiolipin stabilizer that supports electron transport and reduces oxidative stress in multiple mitochondrial disease models. No published statements address plantar fasciitis specifically.\n\n## What people say on Reddit\n\nNo posts or threads were identified discussing SS-31 or elamipretide in the context of plantar fasciitis or foot pain. Searches returned zero relevant anecdotes.\n\n## What people say on X\n\nNo posts were identified linking SS-31 to plantar fasciitis. General discussions of the peptide focus on Barth syndrome approval or mitochondrial myopathy trials.\n\n## What we do not know\n\nNo human trials exist for SS-31 in plantar fasciitis. No animal models of plantar fasciitis treated with SS-31 have been published. Whether improved mitochondrial function in cultured tendon cells translates to fascia repair in vivo remains unknown. Long-term safety and functional outcomes in musculoskeletal tissues are unstudied for this indication. Weight loss can reduce compressive forces on the plantar fascia (roughly 4 lb per pound lost), but SS-31 itself has no documented effect on body weight.\n\n## Safety and limits\n\nSS-31 has been tested in human trials for mitochondrial myopathy and Barth syndrome with generally good tolerability reported. Common side effects in those studies were mild and included injection-site reactions. The compound received FDA approval for Barth syndrome in 2025. All other uses remain investigational. No data exist on interactions with common plantar fasciitis treatments or on long-term use in otherwise healthy individuals. This review reports published findings only and does not constitute guidance.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-plantar-fasciitis/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Degenerative tenocytes from human tendon show increased mitochondrial depolarization that decreases after SS-31 treatment in cell culture.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only direct cellular data on SS-31 in degenerative tendon cells relevant to fascia.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SS-31 improved mitochondrial morphology, superoxide dismutase activity, and reduced MMP-1 and FABP4 gene expression in degenerative tenocytes.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Details the specific mitochondrial and gene changes observed.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human clinical trials of SS-31 have been conducted in plantar fasciitis.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Establishes the evidence gap for the target condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"SS-31 received FDA approval for Barth syndrome in 2025 based on extension-phase functional improvements.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents the approved indication and trial outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No Reddit or X anecdotes mention SS-31 for plantar fasciitis.","section":"What people say on Reddit","tier":"anecdotal","source_ids":[],"source_status":"unsourced","why_material":"Confirms absence of community reports.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35862638/","title":"Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model","quote":"There are changes in mitochondrial structure and function in tenocytes derived from degenerative tendons, and SS-31, as a mitochondrial protectant, could improve mitochondrial function and promote the healing of tendinopathy.","summary":"In vitro study on human tenocytes showing SS-31 effects on mitochondria and gene expression in degenerative cells.","claim_ids":["c1","c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:48:52.430Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"f097611dea886decfb90f89c1a79b20268a7ad37e3160858b599c2aff95e8df3"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35862638/","title":"Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model","quote":"The potential of SS-31 in treating tendinopathy has not been explored.","summary":"Explicit statement of no prior exploration in tendinopathy, extending to plantar fasciitis.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:48:52.430Z","link_status":"ok","quote_status":"verified","prev":"f097611dea886decfb90f89c1a79b20268a7ad37e3160858b599c2aff95e8df3","hash":"27a377688ad1ac77288b9da8d28bbd8a955aa8490671966402bface18b98cda9"},{"id":"s3","type":"news","url":"https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/","title":"FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31","quote":"The recent FDA approval of elamipretide is for the treatment of a rare disease","summary":"Reports 2025 FDA approval for Barth syndrome and trial context.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:48:52.430Z","link_status":"ok","quote_status":"unverified","prev":"27a377688ad1ac77288b9da8d28bbd8a955aa8490671966402bface18b98cda9","hash":"1e32ffca2ef4addbee999fa0885d54ddc81e0f73ab715f6ffef03da5a9527cad"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:48:53.088Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Plantar Fasciitis\n\nPlantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased cell death in tenocyte-like cells, and reduced ability to handle mechanical stress from walking or standing.\n\nIf your fascia cells have mitochondrial dysfunction, energy production drops and repair slows. This creates a gap where breakdown outruns regeneration. Mitochondrial membrane potential falls, reactive oxygen species handling weakens, and genes linked to matrix breakdown rise. These layers matter because plantar fascia is under constant load; poor cellular energy makes recovery harder.\n\nNo direct human data links plantar fasciitis to SS-31. The closest evidence comes from degenerative tendon cells, which share features with fascia degeneration.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. You are reading about Plantar Fasciitis — what breaks down matters before any compound name.\n2. Therefore for you: If mitochondrial dysfunction in fascia cells is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\nSS-31 concentrates in the inner mitochondrial membrane and stabilizes cardiolipin. In degenerative tenocytes from human tendon biopsies, treatment reduced the fraction of cells with depolarized mitochondria and improved mitochondrial number and size seen on electron microscopy. Superoxide dismutase activity rose after treatment. Matrix metalloproteinase-1 expression fell, and fatty acid-binding protein 4 expression dropped. Cell viability showed small improvement.\n\nIf your plantar fascia cells behave like those degenerative tenocytes, SS-31 could support mitochondrial structure and function. That might allow better ATP production for collagen maintenance and reduce signals that promote further breakdown. The study used cultured cells from patients with rotator cuff issues, not foot fascia, so direct translation remains untested.\n\nSS-31 does not act as a pain suppressor or anti-inflammatory drug in the classic sense. It addresses cellular energy deficits that may underlie poor tissue repair in degenerative conditions.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer. If your condition profile includes other degeneration layers such as mechanical overload or inflammation, those would require separate approaches. SS-31 addresses energy production inside cells so repair pathways have a better chance to keep pace with daily loading on the fascia.\n\n## What the evidence actually shows\n\nThe key study is an in vitro model using tenocytes from human degenerative supraspinatus tendons versus healthy hamstring tendons (Zhang et al., 2022, Am J Sports Med). Researchers cultured cells at passage 1 and exposed degenerative cells to 1 μM SS-31 for 72 hours. They measured mitochondrial depolarization, morphology via transmission electron microscopy, antioxidant enzyme activity, gene expression, and cell viability.\n\nFindings: degenerative tenocytes had more depolarized mitochondria and smaller, fewer mitochondria. SS-31 reversed these changes. Antioxidant activity improved. Remodeling and fatty infiltration genes normalized. The study is preclinical (human cells in culture) and does not prove effects in living people with plantar fasciitis.\n\nHuman trials of SS-31 exist for primary mitochondrial myopathy and Barth syndrome. One phase 2/3 trial in Barth syndrome showed functional improvements in the open-label extension but missed primary endpoints in the blinded phase. No trials test SS-31 in plantar fasciitis or any foot condition.\n\n## What scientists say\n\nThe tendinopathy paper concludes that mitochondrial dysfunction appears in degenerative tenocytes and SS-31 may improve mitochondrial function to promote healing. Authors note clinical relevance for tendinopathy but call for further work. Broader reviews describe SS-31 as a cardiolipin stabilizer that supports electron transport and reduces oxidative stress in multiple mitochondrial disease models. No published statements address plantar fasciitis specifically.\n\n## What people say on Reddit\n\nNo posts or threads were identified discussing SS-31 or elamipretide in the context of plantar fasciitis or foot pain. Searches returned zero relevant anecdotes.\n\n## What people say on X\n\nNo posts were identified linking SS-31 to plantar fasciitis. General discussions of the peptide focus on Barth syndrome approval or mitochondrial myopathy trials.\n\n## What we do not know\n\nNo human trials exist for SS-31 in plantar fasciitis. No animal models of plantar fasciitis treated with SS-31 have been published. Whether improved mitochondrial function in cultured tendon cells translates to fascia repair in vivo remains unknown. Long-term safety and functional outcomes in musculoskeletal tissues are unstudied for this indication. Weight loss can reduce compressive forces on the plantar fascia (roughly 4 lb per pound lost), but SS-31 itself has no documented effect on body weight.\n\n## Safety and limits\n\nSS-31 has been tested in human trials for mitochondrial myopathy and Barth syndrome with generally good tolerability reported. Common side effects in those studies were mild and included injection-site reactions. The compound received FDA approval for Barth syndrome in 2025. All other uses remain investigational. No data exist on interactions with common plantar fasciitis treatments or on long-term use in otherwise healthy individuals. This review reports published findings only and does not constitute guidance.","claims":[{"id":"c1","text":"Degenerative tenocytes from human tendon show increased mitochondrial depolarization that decreases after SS-31 treatment in cell culture.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only direct cellular data on SS-31 in degenerative tendon cells relevant to fascia.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"SS-31 improved mitochondrial morphology, superoxide dismutase activity, and reduced MMP-1 and FABP4 gene expression in degenerative tenocytes.","section":"Why SS-31 (Elamipretide) might help you","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Details the specific mitochondrial and gene changes observed.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human clinical trials of SS-31 have been conducted in plantar fasciitis.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Establishes the evidence gap for the target condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"SS-31 received FDA approval for Barth syndrome in 2025 based on extension-phase functional improvements.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents the approved indication and trial outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No Reddit or X anecdotes mention SS-31 for plantar fasciitis.","section":"What people say on Reddit","tier":"anecdotal","source_ids":[],"source_status":"unsourced","why_material":"Confirms absence of community reports.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:48:52.645Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35862638/","title":"Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model","quote":"There are changes in mitochondrial structure and function in tenocytes derived from degenerative tendons, and SS-31, as a mitochondrial protectant, could improve mitochondrial function and promote the healing of tendinopathy.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35862638/","title":"Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model","quote":"The potential of SS-31 in treating tendinopathy has not been explored.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"news","url":"https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/","title":"FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31","quote":"The recent FDA approval of elamipretide is for the treatment of a rare disease","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":15473,"tokens_out":2862,"cost":0.02649625,"prev_hash":"genesis","hash":"f3d7ac422dfb8fbf989b85107e7d16458941364a50c95d8156e970faf4432d2c"}],"provenance":[{"ts":"2026-06-29T23:48:53.088Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Plantar Fasciitis\nSlug: ss-31-plantar-fasciitis\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Plantar fasciitis\",\"condition_key\":\"plantar-fasciitis\",\"primary_peptide\":\"ss-31\",\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":true,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Plantar fasciitis\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"You are reading about **Plantar fasciitis** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Plantar fasciitis** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down if you have Pla","response":"{\n  \"slug\": \"ss-31-plantar-fasciitis\",\n  \"title\": \"SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review\",\n  \"body\": \"## What's breaking down if you have Plantar Fasciitis\\n\\nPlantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased cell death in tenocyte-like cells, and reduced ability to handle mechanical stress from walking or standing.\\n\\nIf your fascia cells have mitochondrial dysfunction, energy production drops and repair slows. This creates a gap where breakdown outruns regeneration. Mitochondrial membrane potential falls, reactive oxygen species handling weakens, and genes linked to matrix breakdown rise. These layers matter because plantar fascia is under constant load; poor cellular energy makes recovery harder.\\n\\nNo direct human data links plantar fasciitis to SS-31. The closest evidence comes from degenerative tendon cells, which share features with fascia degeneration.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\n1. You are reading about Plantar Fasciitis — what breaks down matters before any compound name.\\n2. Therefore for you: If mitochondrial dysfunction in fascia cells is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nSS-31 concentrates in the inner mitochondrial membrane and stabilizes cardiolipin. In degenerative tenocytes from human tendon biopsies, treatment reduced the fraction of cells with depolarized mitochondria and improved mitochondrial number and size seen on electron microscopy. Superoxide dismutase activity rose after treatment. Matrix metalloproteinase-1 expression fell, and fatty acid-binding protein 4 expression dropped. Cell viability showed small improvement.\\n\\nIf your plantar fascia cells behave like those degenerative tenocytes, SS-31 could support mitochondrial structure and function. That might a","tokens_in":15473,"tokens_out":2862,"cost":0,"prev":"genesis","hash":"c78f0d4e578d6a6f28b942eb8d06b734631f6232dff58ce6649b0ca364672c66"},{"ts":"2026-07-17T02:42:07.015Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-plantar-fasciitis","response":"25 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c78f0d4e578d6a6f28b942eb8d06b734631f6232dff58ce6649b0ca364672c66","hash":"0411ce842fed4a5498cb6005be15f12495be19dea3b1399d63b6b46865f63c41"}],"energy":{"passes":2,"tokens_in":15473,"tokens_out":2862,"tokens_total":18335,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"0411ce842fed4a5498cb6005be15f12495be19dea3b1399d63b6b46865f63c41"},"posted_at":"2026-06-29T21:33:24.268Z","created_at":"2026-06-29T21:33:24.268Z","updated_at":"2026-07-17T02:42:07.015Z","machine":{"shape":"article.machine/v1","slug":"ss-31-plantar-fasciitis","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-plantar-fasciitis","json":"https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis","bundle":"https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-plantar-fasciitis","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-plantar-fasciitis\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-plantar-fasciitis\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-plantar-fasciitis\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-plantar-fasciitis | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-plantar-fasciitis","json":"/api/articles/ss-31-plantar-fasciitis","markdown":"/api/articles/ss-31-plantar-fasciitis/bundle?format=markdown","skill":"/api/articles/ss-31-plantar-fasciitis/skill","topology":"/api/articles/ss-31-plantar-fasciitis/topology","versions":"/api/articles/ss-31-plantar-fasciitis/revisions","invocations":"/api/articles/ss-31-plantar-fasciitis/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-plantar-fasciitis","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"7f3f2de0ce8a5034201c1ca4a7cd7a9fffd69583f2df687e57ca7841866b16ae"}}}